Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 285-297

  Ohkura, Tsuyoshi ^a   Fujioka, Youhei ^a   Sumi, Keisuke ^a   Nakanishi, Risa ^a   Shiochi, Hideki ^a   Yamamoto, Naoya ^a   Matsuzawa, Kazuhiko ^a   Izawa, Shoichiro ^a   Ohkura, Hiroko ^a   Kato, Masahiko ^a   Taniguchi, Shin ichi ^a   Yamamoto, Kazuhiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Dipeptidyl peptidase 4 (DPP 4) inhibitor; Insulinogenic index; Japanese; Meal tolerance test; Plasma glucose; Plasma insulin; Real world; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; SITAGLIPTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84919351868     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0071-1     Document Type: Article

References (39)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1987;1988(37):667–87.
2. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48:616–20.
3. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004;36:867–76.
4. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol. 2000;404:239–45.
5. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–84.
6. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.
7. Aaboe K, Knop FK, Vilsbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12:323–33.
8. Azuma K, Rádiková Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:459–64.
9. Kadowaki T, Miyake Y, Kajinuma H. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44–9.
10. Kadowaki T, Yoshinaga H. Risk factors for the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japan. Diabetes Res Clin Pract. 1994;24:123–7.
11. Fujimoto WY. Overview of non-insulin dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med. 1996;13:7–10.
12. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabet Care. 2013;36:1789–96.
13. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabet Res Clin Pract. 2008;79:291–8.
14. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57:383–94.
15. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, Chen L, Snyder K, Ruckle JL, Larson PJ, Davies MJ, Langdon RB, Gottesdiener KM, Wagner JA. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71:429–36.
16. Yoshino G, Tominaga M, Hirano T, et al. The test meal A: a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc. 2006;49:361–71.
17. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabet Res Clin Pract. 2002;55:65–85.
18. Sacks DB. Carbohydrates. In: Burtis C, Ashwood E editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders; 1999. p. 750–808.
19. Ohkura T, Shiochi H, Fujioka Y, et al. 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;12:21.
20. Sumi K, Ohkura T, Yamamoto N, et al. Long-term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion. Diabetol Int. 2013;4:190–6.
21. Ohkura T, Inoue K, Fujioka Y, et al. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. BMC Res Notes. 2013;6:453.
22. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39–40.
23. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323–35.
24. Matsuda A, Kuzuya T. The prevalence of low insulin responders to oral glucose load among groups with various patterns of family history of diabetes. Diabet Med. 1996;13:59–62.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabet Care. 1999;22:1462–70.
27. Lim S, An JH, Shin H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf). 2012;77:215–23.
28. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabet Care. 2011;34:1249–57.
29. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.
30. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–69.
31. Sell H, Blüher M, Klöting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabet Care. 2013;36:4083–90.
32. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2001;17:164–74.
33. Mulvey CK, McNeill AM, Girman CJ, et al. Differential associations of oral glucose tolerance test-derived measures of insulin sensitivity and pancreatic β-cell function with coronary artery calcification and microalbuminuria in type 2 diabetes. Diabet Care. 2014;37:124–33.
34. Møller JB, Pedersen M, Tanaka H, et al. Body composition is main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabet Care. 2014;37:796–804.
35. Inagaki N, JDS/JADEC Committee for Standardized Incretin Measurement. Guideline for Incretin Measurement. http://www.jds.or.jp/uploads/photos/786.pdf. Accessed May 16, 2014.
36. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
37. Chung HS, Suh S, Kim MY, et al. Predictive factors of durability to sitagliptin: slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin. J Diabet Invest. 2014;5:51–9.
38. Rijkelijkhuizen JM, Girman CJ, Mari A, et al. Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabet Res Clin Pract. 2009;83:280–8.
39. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab. 2006;91:2062–7.